All In Biotech

Drug Trial Radar · NCT04965675

A Study With Eptinezumab in Adolescents (12-17 Years) With Chronic Migraine

Interventional, Randomized, Double-blind, Parallel-group, Placebo-controlled Study to Evaluate the Efficacy and Safety of IV Eptinezumab in Adolescents (12-17 Years) for the Preventive Treatment of Chronic Migraine

Last checked: Nov 20, 2026Latest source record: Oct 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 285 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

285

Planned (sponsor's estimate)

Start

Jun 30, 2021

Primary completion

Mar 26, 2027

Study completion Mar 26, 2027

Sponsor

Lead sponsor
H. Lundbeck A/SIndustry
Sponsor type
Industry
First posted
Jul 16, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 12 years, up to 17 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

To find out if eptinezumab is better than placebo (normal saline solution) in lowering the number of days with migraine in young people ages 12 to 17 with chronic migraine.

Conditions

  • Chronic Migraine in Children

Interventions

  • EptinezumabDrug

    Eptinezumab will be administered per dose and schedule specified in the arm.

  • PlaceboDrug

    Placebo matching to eptinezumab will be administered per schedule specified in the arm.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change From Baseline in Monthly Migraine Days (MMDs) Averaged Over Weeks 1-12Time frame: Baseline, Weeks 1-12

Locations

79 sites in 11 countries. Site status is shown where the registry gives one.

  • Yale-New Haven Children's Hospital

    New Haven, Connecticut · Completed

  • New England Institute for Clinical Research (NEICR) - Stamford

    Stamford, Connecticut · Recruiting

  • Children's National Hospital - Children's National Heart Center

    Washington D.C., District of Columbia · Completed

  • Sarkis Clinical Trials - Gainsville

    Gainesville, Florida · Completed

  • NW FL Clinical Research Group, LLC

    Gulf Breeze, Florida · Recruiting

  • AGA Clinical Trials

    Hialeah, Florida · Recruiting

  • Axcess Medical Research - Loxahatchee

    Loxahatchee Groves, Florida · Completed

  • University of South Florida (USF) - Tampa Campus

    Tampa, Florida · Recruiting

  • Clinical Integrative Research Center of Atlanta (CIRCAtl)

    Atlanta, Georgia · Completed

  • UK HealthCare-Kentucky Clinic

    Lexington, Kentucky · Recruiting

  • University of Maryland-Marlene and Stewart Greenebaum Cancer Center

    Baltimore, Maryland · Completed

  • Michigan Headache & Neurological Institute (MHNI)

    Ann Arbor, Michigan · Completed

  • Corewell Health - Butterworth Hospital

    Grand Rapids, Michigan · Completed

  • Dent Neurosciences Research Center

    Amherst, New York · Completed

  • True North Neurology - Commack (North Suffolk Neurology)

    Commack, New York · Completed

  • OnSite Clinical Solutions, LLC - Charlotte

    Charlotte, North Carolina · Completed

  • Cincinnati Children's Hospital Medical Center-Burnet Campus

    Cincinnati, Ohio · Recruiting

  • University of Oklahoma Health Sciences Center (OUHSC) - Stephenson Oklahoma Cancer Center

    Oklahoma City, Oklahoma · Completed

  • Road Runner Research (RRR)

    San Antonio, Texas · Recruiting

  • Children's Specialty Group (CSG)

    Norfolk, Virginia · Recruiting

  • MultiCare Mary Bridge Children's Hospital and Health Center

    Tacoma, Washington · Completed

  • Marshall Health-Marshall University Medical Center

    Huntington, West Virginia · Recruiting

  • Clinica Independencia

    Buenos Aires, Argentina · Completed

  • Hospital Italiano de Buenos Aires (HIBA) - Centro de Esclerosis Multiple Buenos Aires (CEMBA)

    Buenos Aires, Argentina · Completed

  • Hospital Britanico de Buenos Aires (HOB)

    Buenos Aires, Argentina · Completed

  • Hospital Privado de Comunidad (HPC)

    Mar del Plata, Buenos Aires, Argentina · Completed

  • Mautalén Salud e Investigación

    Buenos Aires, Buenos Aires F.D., Argentina · Completed

  • Hospital de Niños de la Santísima Trinidad

    Córdoba, Córdoba Province, Argentina · Recruiting

  • Instituto Médico Río Cuarto

    Río Cuarto, Córdoba Province, Argentina · Recruiting

  • Sanatorio Allende S.A.

    Córdoba, Cordoba, Argentina, Argentina · Completed

  • INECO Neurociencias Oroño

    Rosario, Santa Fe Province, Argentina · Recruiting

  • Centro de Investigaciones Medicas Tucuman

    San Miguel de Tucumán, Tucumán Province, Argentina · Recruiting

  • University of Alberta Hospital (UAH)

    Edmonton, Alberta, Canada · Completed

  • The Medical Arts Health Research Group - Penticton

    Penticton, British Columbia, Canada · Completed

  • Vancouver Island Health Authority (VIHA) - Multiple Sclerosis (MS) Clinic

    Victoria, British Columbia, Canada · Recruiting

  • Kids Clinic

    Ajax, Ontario, Canada · Recruiting

  • London Health Sciences Centre (LHSC)

    London, Ontario, Canada · Recruiting

  • Istituto Giannina Gaslini IRCCS

    Genoa, Italy · Recruiting

  • Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta

    Milan, Italy · Completed

  • Fondazione Mondino, IRCCS Istituto Neurologico Nazionale a Carattere Scientifico

    Pavia, Italy · Recruiting

Showing 40 of 79 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.